Metabolite and gut microbiota co-biomarkers in Danggui Shaoyao San: insights into a shared therapeutic approach

当归芍药散中代谢物和肠道菌群的共生物标志物:对共同治疗方法的启示

阅读:1

Abstract

Danggui Shaoyao San (DSS), a classical multi-herbal formulation of traditional Chinese medicine, demonstrates therapeutic potential for Type 2 Diabetes Mellitus (T2DM), Alzheimer's Disease (AD), and Polycystic Ovary Syndrome (PCOS). This review proposes a unified mechanism whereby DSS exerts its effects by modulating a network of shared pathological biomarkers across these disorders. We identify tryptophan (Trp) and phenylalanine (Phe) as host-derived metabolic biomarkers in plasma, and the gut bacterial phylum Bacteroidetes as a shared gut microbial biomarker. The therapeutic actions of DSS are mediated by its botanical constituents (e.g., ligustilides, paeoniflorin, ferulic acid), which help correct the dysregulated Trp-kynurenine and Phe metabolic pathways, while simultaneously enriching Bacteroidetes to alleviate gut dysbiosis and rebalance the gut-brain axis. This coordinated regulation of shared host metabolic and gut microbial biomarkers provides a scientific rationale for applying DSS as a multi-targeted agent, illustrating a molecular basis for a shared therapeutic approach.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。